The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis
- NHS Economic Evaluation Database - NHS EED
- Publication date:
- 30 April 2004
Bibliographic detailsMaetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and Rheumatism (Arthritis Care and Research) 2003; 49(3): 283-292
StatusThis is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Indexing statusSubject indexing assigned by NLM
Index termsAged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal /adverse effects /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy /physiopathology; Canada; Cost-Benefit Analysis; Cyclooxygenase Inhibitors /adverse effects /economics /therapeutic use; Drug Costs; Female; Gastrointestinal Diseases /chemically induced; Humans; Lactones /adverse effects /economics /therapeutic use; Male; Markov Chains; Middle Aged; Osteoarthritis /drug therapy /physiopathology; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides /adverse effects /economics /therapeutic use; Sulfones